查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球人造子宮市場
市場調查報告書
商品編碼
1217635

2023-2030 年全球人造子宮市場

Global Artificial Womb Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

人造子宮可以用來在體外培育胎兒。 因此，胎兒心臟和臍帶是維持血液循環的條件。 如果滿足這些條件，可以在分娩前從天然子宮轉移到人工子宮模擬分娩。 EctoLife 是世界上第一個人造子宮設施，目前是一個完全由可再生能源提供動力的概念。 50 多年的全面和突破性的科學研究將使我們每年能夠養育約 30,000 名嬰兒。 這是居住在柏林的科學生物技術專家和傳播者 Hashem Algaili 的心血結晶。 此外，胚胎可以在植入人造子宮之前進行基因操作。

市場動態

不孕□□症、流產、死產和人造子宮研究的興起預計將在預測期內推動全球人造子宮市場的增長。

不孕□□症、流產和死產的增加將推動預測期內人造子宮市場的增長。

不孕□□症，或嘗試超過一年後仍無法懷孕，對個人和夫婦來說都是困難的。 不孕症非常普遍，懷孕甚至會導致死產或流產。 全球不孕症患者數量的增加正在推動人造子宮市場的增長。 例如，UCLA Health 在 2020 年估計約有 15% 的夫婦難以懷孕。 此外，根據 Fertility Answers，大約 30% 的不孕症完全由女性引起，30% 完全由男性引起，30% 由雙方混合引起，還有 10% 不明原因。是

此外，全球死產和流產的增加也促進了市場增長。 例如，根據 UNICEF.org 的數據，世界上每 16 秒就會發生一例死產，相當於每年約有 200 萬嬰兒死產，據說成本遠遠超過失去的生命。我來了。 到 2021 年，每 16 秒將有大約 190 萬嬰兒死產。 最新數據顯示，2020年全球死產率為千分之13.9，其中40%以上發生在分娩過程中。 它對世界各地的婦女及其家庭產生了長期的創傷性影響，常常給社區帶來深深的情緒困擾和污名化，即使在高收入國家也是如此。

此外，根據耶魯大學醫學院的數據，15-20% 的懷孕以流產告終，大約 2% 的女性連續流產兩次，但這很可能是環境造成的。 根據 ACOG（美國婦產科學院）的數據，近 5% 的女性有 2 次或更多次流產，1% 有 3 次或更多次流產。 35 歲以上的女性和有過流產史的女性更有可能發生反復流產。 很少有流產病例被報導，因為許多婦女在知道自己懷孕之前就流產了，並且沒有任何流產的跡像或症狀。 大多數流產是由胚胎或胎兒的遺傳異常引起的，例如額外的染色體或染色體突然出現。 這些是自然界中不存在且不太可能再次發生的突變。 但對於反復流產，情況就不同了，醫生會尋找一種稱為平衡易位的經典突變類型。 鑑於上述情況，預計在預測期內，不孕症、死產和流產的增加將提振全球人造子宮市場。

倫理問題和人造子宮的高成本可能會抑制全球人造子宮市場的增長。

但是，批准的道德要求作為市場限制了預測期內的增長。 同樣，由於該技術具有創新性和安全性，因此建造人造子宮的成本高得令人望而卻步，這使得中低收入者無法承受。 據推測，這些因素會阻礙未來幾年的市場擴張。

COVID-19 的影響。

COVID-19 大流行期間 SARS-CoV-2 陽性母親的流產、胎兒生長受限和死產等妊娠相關並發症的發生率似乎更高，這也是人類生育的未來。成為一個問題。 對此類未來大流行的擔憂已將注意力集中在開發進行人類懷孕和分娩的新方法上。 因此，它對全球人造子宮市場的增長產生了積極影響。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 不孕症、流產和死產率增加
      • 調查與研發
    • 約束因素
      • 道德問題和高成本
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 定價分析
  • 未滿足需求分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

最終用戶第 7 章

  • 研究中心
  • 專科醫院
  • 其他

第8章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第9章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準

第十章公司簡介

  • Juno Perinatal Healthcare
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • EctoLife

第11章 DataM

簡介目錄
Product Code: DMMD6260

Market Overview

The global Artificial Womb market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

An artificial womb can be used to carry a fetus to term outside of the body. As a result, requirements include a fetal heart and an umbilical cord to maintain circulation. When these conditions are satisfied, the baby can be transferred from a natural uterus to an artificial one, simulating giving birth before delivery. EctoLife, the first artificial womb facility in the world, is a concept that, for now, is entirely powered by renewable energy. It will have the capacity to grow around 30,000 babies every year, owing to the comprehensive and groundbreaking scientific investigation of over five decades. It is the brainchild of Hashem Al-Ghaili, a science biotechnologist and communicator from Berlin. It would also let them genetically engineer the embryo before implanting it into an artificial womb.

Market Dynamics

The rising number of infertility cases, miscarriages, and stillbirths and the research on artificial wombs will promote the global artificial womb market growth in the forecast period.

The growing number of infertility cases, miscarriages, and stillbirths drive the artificial womb market growth during the forecast period.

Infertility, or the inability to get pregnant even after attempting for over a year, can be challenging for individuals and couples. Infertility is fairly ordinary, and it can even mean getting pregnant but having stillbirths or miscarriages. The growing number of infertility cases globally boosts the artificial womb market growth. For instance, UCLA Health in 2020 estimated that about 15% of couples would have trouble conceiving. Also, according to Fertility Answers, about 30% of infertility cases can be attributed solely to the female, 30% can be attributed solely to the male, 30% can be attributed to a mixture of both partners, and 10% of cases have an unidentified reason.

Moreover, the growing incidences of stillbirths and miscarriages globally will also contribute to market growth. For example, according to UNICEF.org, a stillbirth occurs every 16 seconds worldwide, which means that every year, approximately 2 million babies are stillborn, a loss that goes far above the loss of life. Roughly 1.9 million babies, or one every 16 seconds, were stillborn in 2021. According to the latest data, the global stillbirth rate in 2020 was 13.9 stillbirths per 1,000 total births, and over 40% of all stillbirths happened during labor. It has a long-lasting traumatic influence on women and their families worldwide, who often bear deep psychological torment and stigma from their communities, even in high-income countries.

Similarly, according to Yale Medicine, almost 15 to 20% of pregnancies end in miscarriage, and roughly 2% of women experience two consecutive pregnancy losses, which could still be attributed to circumstance. Also, according to ACOG (American College of Obstetricians and Gynecologists), almost 5 % of women have two or more consecutive miscarriages, and 1 % might have three or above. The chance of recurrent miscarriage is elevated in women over 35 or with previous miscarriages. The cases of miscarriage are mostly underreported, as many women have miscarriages before they even know they are pregnant and do not experience any signs or symptoms of the miscarriage. The bulk of miscarriages happens due to genetic anomalies in the embryo or fetus, like an extra chromosome or skipping chromosomes. These are naturally unexpected mutations that are not probably to recur. In recurrent miscarriage, nevertheless, the situation is distinct, and the doctor will examine for a typical type of mutation called a balanced translocation. Thus, from the mentioned data, it is estimated that the growing cases of infertility, stillbirths and recurring miscarriages will push the global artificial womb market during the forecast period.

The ethical concerns and the high cost of the artificial womb will restrain the growth of the global artificial womb market.

However, the ethical requirements for approval function as a market will restrain its growth in the forecast period. Again, building an artificial womb will be highly expensive because the technology is innovative and safe, making it unaffordable to low and middle-income individuals. These factors are estimated to hamper the market expansion in the upcoming years.

COVID-19 Impact.

The COVID-19 pandemic created a concern about the future of human births since, during the pandemic period; it appeared to be a higher incidence of pregnancy-related complications in SARS-CoV-2 positive mothers, such as miscarriage, restricted fetal growth, or still-birth. Such future pandemic concerns are increasing the focus on developing new ways to carry out human gestation birth. Thus, positively impacting the global artificial womb market growth.

Segment Analysis

The research centers segment is expected to dominate the market throughout the forecast period (2022-2029).

Due to many initial projects in the pipeline, the research centers segment dominates the market. For instance, in 2020, the JUNO Perinatal Healthcare partnership is working to create a medical device, or "artificial womb," that enables extremely preterm infants to grow safely outside the womb. These infants will ultimately have better health chances than premature infants receiving standard care. The project received a Future and Emerging Technologies grant from the European program Horizon 2020 of almost 3 million euros. In this project, the researchers plan to finish a proof-of-principle in 5 years. And in 2021, using an artificial "womb" invented by scientists at the Weizmann Institute, early-stage mouse embryos with about 250 cells successfully developed into mouse fetuses with completely developed organs, which was made in Professor Jacob Hanna's Department of Molecular Genetics lab. The novel technique addresses a key issue in developmental biology: much of what is known about embryonic development comes from non-mammals like frogs or fish or is inferred from static photographs of mouse embryos because it is difficult to imagine or implant inside the uterus. With the help of this technique, Prof. Hanna and his team have generated fetuses that live until day 11, by which time the embryo has grown tenfold and is complete with blood, a beating heart, and a completely formed brain, which might lead to the development of fresh tactics for better medical care.

Geographical Analysis

Europe is expected to hold the largest global artificial womb market share.

The growing rate of infertility, stillbirths and miscarriage in Europe is expected to contribute to the region's hold on the global artificial womb market in the forecast period. For instance, according to NHS, in England, around 1 out of 250 births is a stillbirth. Not all the reasons for stillbirth are presently comprehended, and it's impossible to prevent every stillbirth. Also, according to the Tommy's Organization, a registered charity in England and Wales and Scotland, it is estimated that 1 in 4 pregnancies end in loss during pregnancy or birth, as there were around 500 miscarriages, 2,638 stillborn, and over 60,000 were born prematurely in the UK in 2020. Moreover, according to the National Bureau of Economic Research, as in many parts of the world, Europe has seen a rapid decline in fertility. For instance, according to Eurostat, over 4.071 million children were born in the EU, corresponding to a crude birth rate (the number of live births per 1 000 persons) of 9.1 in 2020. For comparison, the EU crude birth rate was 10.5 in 2000, 12.8 in 1985 and 16.4 in 1970.

Furthermore, the different initiatives in Europe to spread awareness about the declining birth rate, rising infertility rate and developments towards artificial womb research. For instance, the Wittgenstein Centre for Demography and Global Human Capital (IIASA, OeAW, University of Vienna) held its annual conference. The focus of the 2021 conference was on the causes and consequences of depopulation, an issue very much in the spotlight of the European Commission and beyond. Also, the Horizon 2020 EU program has awarded a research grant of €2.9 million to the Eindhoven University of Technology for researchers to develop artificial womb prototypes. In addition, Lisa Mandemaker presented a speculative design proposal for an artificial womb in close collaboration with Maxima Medical Centre (MMC) in the Netherlands. Thus, from the data mentioned, it is estimated that Europe will dominate the global artificial womb market throughout the forecast period.

Competitive Landscape

Currently, there is no present competition in the artificial womb market due to the absence of key players. Still, the market is expected to show moderate competition in the future owing to new players entering the market. Currently, only some players are working on the research project, which is expected to hold most of the market to themselves. For example,

Juno Perinatal Healthcare

Overview:

Juno Perinatal Healthcare is a spin-off enterprise of and confidante to the PLS project. The startup was established in July 2021 by engineers Jasmijn and Lyla Kok, medical engineer Beatrijs van der Hout, technician physician Dr. Myrthe van der Ven and Gynecologist prof. Dr. Guid Oei. Juno aspires to assure that the innovative perinatal life support technology developed in the PLS project will go to market.

Project:

The JUNO Perinatal Healthcare consortium is developing a medical device, an artificial womb, that supports the safe development of premature babies outside of the womb. Ultimately, these infants will have better health prospects than premature infants with conventional care.

The global artificial womb market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Number of Infertility Cases, Miscarriages, And Stillbirths
      • 4.1.1.2. Research and Developments
    • 4.1.2. Restraints
      • 4.1.2.1. The ethical concerns and the high cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By End User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 7.1.2. Market Attractiveness Index, By End User
  • 7.2. Research Centers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Specialty Hospitals
  • 7.4. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.4.1. U.S.
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.4.1. Germany
      • 8.3.4.2. U.K.
      • 8.3.4.3. France
      • 8.3.4.4. Italy
      • 8.3.4.5. Spain
      • 8.3.4.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.4.1. Brazil
      • 8.4.4.2. Argentina
      • 8.4.4.3. Rest of South America
  • 8.5. Asia Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.4.1. China
      • 8.5.4.2. India
      • 8.5.4.3. Japan
      • 8.5.4.4. Australia
      • 8.5.4.5. Rest of Asia Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

9. Competitive Landscape

  • 9.1. Key Developments and Strategies
  • 9.2. Company Share Analysis
  • 9.3. Product Benchmarking

10. Company Profiles

  • 10.1. Juno Perinatal Healthcare
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Key Highlights
    • 10.1.4. Financial Overview
  • 10.2. EctoLife

LIST NOT EXHAUSTIVE

11. DataM

  • 11.1. Appendix
  • 11.2. About Us and Services
  • 11.3. Contact Us